

## ICBP Phase 2 Academic Reference Groups

### ICBP SurvMark-2 (survival benchmark)

<b>Sabine Siesling</b> <i>Netherlands</i>	<p>Sabine works at University of Twente and is involved in several (inter-) national studies (i.e. National Cancer Control Plan, trends in cancer in the Netherlands, EURO CARE, RARE CARE, EUROCHIP, EURO COURSE). Her main interests are the role of interventions (reaching from care pathways to technological innovations) in quality and cost-effectiveness of oncological care (i.e. in breast, lung, colorectal and rare cancers). She is involved in the project concerning the individualization of follow-up programs for cancer patients. She is interested in the specific role of imaging techniques in oncological care in relation to geographical differences in incidence and outcome (i.e. cervical cancer, mesothelioma, melanoma) is topic of interest.</p>
<b>Dianne O’Connell</b> <i>Australia</i>	<p>Diane has extensive experience in designing and analysing epidemiological studies and randomised controlled trials. She has extensive experience in analysing large, routinely collected datasets. Dianne leads studies on the variation in the management and treatment of major cancers in NSW and the analysis of data from the NSW Central Cancer Registry.</p>
<b>Diana Sarfati</b> <i>New Zealand</i>	<p>Diana is a public health physician and epidemiologist at the University of Otago with a particular interest in the interface between public health and clinical medicine. She is co-Head of the Department of Public Health and the Director of the Cancer and Chronic Conditions (C3) research group. Professor Sarfati has a range of research interests relating to cancer, long term conditions and health services. She has led a large body of work relating to ethnic disparities in cancer outcomes. This work has resulted in the identification of key patient and health system factors that influence cancer survival. This work has been used extensively by health policy makers, clinicians and other researchers to develop policies and practices that aim to reduce inequities in cancer outcomes. Professor Sarfati has a strong interest in research focused on multimorbidity in general, and in the context of cancer specifically.</p>
<b>Michael Eden</b> <i>England</i>	<p>Michael is a consultant Histopathologist and Cytopathologist at Cambridge University Hospitals NHS Foundation Trust. Michael is also an associate medical director for the national cancer registration and an associate Caldicott guardian. Michael was one of the lead researchers on Workstream 1 of Module 5 of ICBP looking at the differences in cancer registration between jurisdictions.</p>
<b>Brian Rous</b> <i>England</i>	<p>Brian is the Chair of the National Cancer Intelligence Network National Staging Panel, Senior Visiting Scientist in Section of Cancer Surveillance at IARC.</p>

## Phase 2 (health systems, cancer pathways, access to diagnostics and treatment)

<p><b>Philippe Michel</b> <i>France</i></p>	<p>Philippe Michel, MD, PhD, is professor of public health, head of the healthcare organization performance department of the HESPER research unit (Health Services and Performance research, EA 7425) at University Lyon. He is also the quality and safety director of the Lyon hospital, the second-largest University Hospital Network in France. At national level, he is the president of the “Healthcare system and patient Safety” Commission at the High Council for Public Health (HCSP), an advisory body for the Minister of Health; member of the scientific board of the French National Health Insurance Fund (CNAMTS); He is president of Experience Patient France (EPF). His research interests are in the patient safety and quality indicators domains. He was in charge of the two National surveys on adverse events in France in 2004 and 2009 (ENEIS). He was involved in several projects on development, validation and assessment of mandatory national quality indicators. He is a regular WHO expert in Patient Safety and External lead of a WHO project on Patient Safety Research methodologies.</p>
<p><b>Isabelle Ray-Coquard</b> <i>France</i></p>	<p>Isabelle Ray-Coquard, MD, PhD, is medical oncologist in the Medical Oncology Department and the Institute for Clinical Science at the Centre Leon Berard, the regional Cancer Center in Lyon, France. She is also Professor of Medical Oncology in University Claude Bernard Lyon I, France. Since 2005, she has served as Chairman of the gynaecologic group for clinical trials of the French National Cancer Institute (INCA) and she is currently the Network Director of the national observatory dedicated to rare ovarian cancer (<a href="http://www.ovaire-rare.org">www.ovaire-rare.org</a>), a network funded by the INCA commission and dedicated to the management of all rare ovarian cancer. Prof. Ray-Coquard is an active member of a number of professional groups, including the American Society of Clinical Oncology, the American Association for Cancer Research, the Connective Tissue Oncology Society, the French Society of Cancer, the European Association of Cancer Research, the EORTC organisation and the European Society of Medical Oncology.</p>
<p><b>Jackie Cumming</b> <i>New Zealand</i></p>	<p>Jacqueline Cumming is Professor of Health Policy and Management and Director of the Health Services Research Centre in the Faculty of Health at Victoria University of Wellington, New Zealand. She has qualifications in both economics and public policy. Jacqueline previously worked for a number of government departments and agencies, including the Public Health Commission and the Department/Ministry of Health, and spent time on secondment to the Health Services Taskforce and the Core Services Committee secretariat. Her research interests include health economics and health policy issues, particularly priority setting, core services, economic evaluation and health services structures and policy. Her PhD in Public Policy at Victoria University of Wellington focused on the theory and practice of defining core health services. As well as managing the Centre, she is working on a number of projects, including projects researching primary health care service delivery reform, integration for Pacific families, and ageing well.</p>
<p><b>Jane Young</b> <i>New South Wales</i></p>	<p>Jane Young is Professor in Cancer Epidemiology at the University of Sydney and leads the Cancer Epidemiology and Services Research (CESR) group within the Sydney School of Public Health and has an advisory role as Scientific Director of the Cancer Institute NSW (CINSW). Since 2002, she has been the Executive Director of the Surgical Outcomes Research Centre (SOuRCe), a conjoint multidisciplinary research unit of Sydney Local Health District and the University of Sydney. Jane’s research focuses on the application of epidemiological methods to improve cancer services and outcomes, the evaluation of surgical outcomes, the promotion of evidence based practice and the use of data to improve cancer service delivery. She is a member of the Governing Council of the Sydney Catalyst translational cancer research centre and serves on the Evidence into Practice (T2/T3) Working Party. She has co-authored over 120 peer-reviewed journal articles, has attracted approximately \$10M in research grant funding and currently supervises 10 postgraduate students.</p>
<p><b>Kathy Pritchard-Jones</b></p>	<p>Professor Kathy Pritchard-Jones is Programme Director for the Integrated Cancer Programme at UCLPartners and Chief Medical Officer for London Cancer. Through these roles she has led the development of the London Cancer integrated cancer system, a new way of organising</p>

<p><i>England</i></p>	<p>cancer care in north central and east London and west Essex, which focuses cancer care on the needs of the patient. She is one of the UK's foremost experts in childhood cancer, has been a consultant in the field for 20 years and is currently professor of Paediatric oncology at the UCL Institute of Child Health and honorary consultant oncologist at Great Ormond Street NHS Foundation Trust. She heads a laboratory for research into the molecular biology of childhood renal tumours, principally Wilms' Tumour. Her group is researching improving risk stratification and more personalised treatment made possible by molecular medicine, to give children the best chance of a long-term cure without undue risky and potentially damaging side-effects. Kathy is one of four key leaders of the major FP7 funded European Network for Cancer research in Children and Adolescents (ENCCA) and Vice Chair of the International Society of Paediatric Oncology (SIOP) Renal Tumours Study Group, responsible for phase I-III clinical trials in Europe.</p>
<p><b>Nancy Keating</b> <i>United States</i></p>	<p>Dr. Keating's research examines provider, patient, and health system factors that influence the delivery of high-quality care for individuals with cancer. Dr. Keating is a longstanding member of the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium, funded by the National Cancer Institute (NCI). This is a collaborative effort among investigators at seven sites to examine patterns of care and outcomes for patients with colorectal and lung cancer. Using CanCORS data linked with Medicare administrative data, she is seeking to better understand patient, physician, and health system factors contributing to the variations in the intensity of end-of-life (EOL) care for individuals with advanced cancer. She is an associate editor at the Journal of the National Cancer Institute, a member of the editorial board of the Journal of Geriatric Oncology, and a member of the National Comprehensive Cancer Center Senior Oncology Guideline Panel. She recently completed 3-year terms on the Council of the Society of General Internal Medicine and the American Society of Clinical Oncology Clinical Practice Guidelines Committee. Dr. Keating recently served on the Institute of Medicine Committee: Clinical Guidance for the Care of Health Conditions Identified by the Camp Lejeune Legislation.</p>
<p><b>Angela Mariotto</b> <i>United States</i></p>	<p>Angela Mariotto is the Chief of the Data Analytics Branch (DAB) of the Surveillance Research Program (SRP) within the Division of Cancer Control and Population Sciences (DCCPS) at the National Cancer Institute (NCI). Dr. Mariotto received her Doctor of Philosophy degree in Statistics from Imperial College, London, UK. Dr. Mariotto's research interests include development and improvement of cancer progress measures, in particular survival, prevalence, health care utilization, and cost measures. Her other areas of expertise include the development and application of models to predict and project, incidence, prevalence and survival and new approaches for the analysis, reporting, and visualization of cancer surveillance data. She is the NCI scientific coordinator of the prostate cancer working groups in the Cancer Intervention and Surveillance Network (CISNET) cooperative agreement, for which she coordinates research activities of grantees who are investigating the impact of interventions on prostate cancer outcomes. Dr. Mariotto has won numerous NIH merit awards and is the author of over 100 papers in particular in the area of development and applications of cancer control and surveillance measures using cancer registry data.</p>
<p><b>Stuart Peacock</b> <i>British Columbia</i></p>	<p>Stuart Peacock holds the Leslie Diamond Chair in Cancer Survivorship in the Faculty of Health Sciences, Simon Fraser University. He is Co-Director of the Canadian Centre for Applied Research in Cancer Control (ARCC) and Head of Cancer Control Research at the BC Cancer Research Centre. He is also a member of the Board of Directors of the Canadian Agency for Drugs and Technologies in Health, and past President of the International Society on Priorities in Health Care. He has held university positions in Canada, Australia and the UK. Stuart's expertise is in the economics of cancer control and quality of life for those impacted by cancer. His main research interests include developing more effective cancer services, making health system funding decisions fairer and more transparent, and improving the quality of life of cancer patients and survivors.</p>